@notablelabs team members were energized by the response to our poster at the 12th annual meeting of the @SocietyofHemOnc (SOHO2024)!  We were privileged to join cutting-edge research companies presenting the latest breakthrough research.  We remain committed to being the leader in predictive medicine and to revolutionize how patients seek and receive treatments that work best for them. #SOHO2024 #hemonc #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

Don't miss the @notablelabs poster, “Revival of the Polo-Like Kinase 1 (PLK1) Inhibitor Volasertis In Relapsed/Refractory Acute Myeloid Leukemia,” presented at the twelfth annual meeting of the @SocietyofHemOnc (SOHO 2024), September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas. #SOHO2024 #hemonc #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

Our team at @notablelabs  is looking forward to attending the twelfth annual meeting of the @SocietyofHemOnc (SOHO 2024), September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.  We look forward to learning about the latest breakthroughs in the research and treatment of patients with hematologic malignancies and collaborating in real time with our colleagues.  Contact us at to set up an appointment. #SOHO2024 #hemonc #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

ICYMI: @notablelabs poster, “Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples,” presented at the American Association for Cancer Research (@AACR ) 2024 in San Diego, CA (Abstract 2548). Kudos to Lokesh Patil, Notable Labs Platform Lead, who served as the lead author and poster presenter, as well as Oregon Health & Science University abstract co-authors Nicola Long and Christina Tognon, PhD. These data suggest Ex vivo drug sensitivity assay using cryopreserved patient samples in the PPMP assay can predict clinical response. Please visit #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS @OHSUNews @OHSUSOM

Check out @notablelabs poster, “Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients,” presented last week at the @AACR 2024 Annual Meeting in San Diego, CA (Abstract 5178).  Congratulations to Markus Lacher, Notable Labs VP of R&D who served as the lead author and poster presenter.  These data suggest a strong correlation between volasertib resistant fractions treated with 31.6 and 100 nM of volasertib and AUCs, which could represent a suitable metric to stratify patients into responders and non-responders. These preliminary metrics predict that 32-33% of de novo patients and 25% of R/R AML patients would be predicted to be responders if they were treated with volasertib. Please visit @StanfordDeptMed #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS #Volasertib

@notablelabs will present the following two posters at the American Association for Cancer Research  (@AACR ) Annual Meeting, April 5-10, 2024, in San Diego, CA: 1. Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients (poster section 45, poster #19, abstract #5178).  Session Date and Time: Tuesday April 9, 2024, 9:00 AM - 12:30 PM (PT) 2. Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples (poster section 45, poster #8, abstract #2548).  Session Date and Time: Monday April 8, 2024, 9:00 AM - 12:30 PM (PT) #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

Learn how @notablelabs is pioneering the integration of artificial intelligence (AI) into predictive precision medicine in this informative @CALifeSciences article, written by Chris Leonardi, Head of Clinical Alliances and Partnerships. Chris explores how predictive precision outcomes compare to traditional methods, as was showcased at the 2023 @AACR annual meeting. He also describes how AI’s ability to navigate complex datasets without prior knowledge of a drug’s specific cellular biology contributes to a comprehensive understanding of drug efficacy. Read more at #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS #AcuteMyeloidLeukemia #artificial intelligence #AI #drugefficacy

@notablelabs Predictive Precision Medicine Platform (PPMP) uses AI and machine learning to provide a predictive score for a patient's likelihood to respond to a particular cancer treatment. NOTABLE’s PPMP is designed to identify and select clinically responsive patients prior to their treatment while also expediting clinical development in this patient population. NOTABLE is revolutionizing the way patients seek and receive treatment. Questions? Let’s talk: info@notablelabs.com. Learn more at #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS

@notablelabs announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders.  Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML).  “PPMP’s recently reported, 100% accurate prediction of fosciclopirox’s clinical trial outcome has allowed us to eliminate an entire 30-patient cohort from the planned volasertib program,” said Thomas Bock, M.D., Chief Executive Officer of Notable Labs. “This further validates our PPMP-guided development strategy to target responding patients, improve patient outcomes and reduce the risk, time, and cost of drug development.”  More information at #fosciclopirox #PPMP #drugdevelopment #hematology #hematologists #bloodcancer #precisionmedicine #leukemia #AML #MDS #cancerresearch

@Notable Labs is proud of the world-class team it has assembled to develop its proprietary Predictive Precision Medicines Platform (“PPMP”) technology. We are extremely excited to have Joseph Wagner, PhD, serving as our chief scientific officer. #hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS

The @notablelabs Predictive Precision Medicines Platform (“PPMP”) has been validated across four clinical studies conducted at global academic cancer research centers.  Through our proprietary PPMP technology, Notable bio-simulates a cancer treatment and aims to predict whether a patient is likely to respond to that specific therapeutic.  Message us at to learn more. #hematology #hematologists #bloodcancer #precisionmedicine #leukemia #AML #MDS #cancer research

Exemplifying the company's strong commitment to research and development of precision treatments for MDS, @notablelabs has donated $60,000 to the @MDSFoundation . The donation was formally announced during the MDS Foundation 2023 Satellite Symposium at the 65th @ASH_hematology (#ash23 ) Annual Meeting which Notable Labs also supported. "Supporting the MDS Foundation directly aligns with our desire to affect positive change for patients affected by this cancer with high unmet need,” said Thomas A. Bock, MD, MBA, CEO, Notable Labs. “Furthermore, the donation helps to fund the dedicated researchers who work tirelessly to find cures for this rare, often undetected disease."  #ASH23 #hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS

ICYMI: @notablelabs was featured on the front page of the December 10/11, Hematology Daily News distributed at @ASH_hematology (#ASH23) conference in San Diego. The article, “The Promise of Predictive Medicine is Coming True,” explains how Notable Labs is advancing predictive precision medicine.  According to the article, “Instead of focusing precision medicine on targeting molecular aberrations most likely leading to cancer response, Notable focuses precision on targeting cancer response itself, i.e., on targeting – with precision – the patients most likely to clinically respond to a treatment.”  #hematology #hematologists #bloodcancer #precisionmedicine #AML #MDS

See @notablelabs Booth #2454 @ASH_hematology Dec. 9-12 & sched. meeting. Learn about PPMP & volasertib, potent PLK1 inhibitor proven to induce cell cycle arrest & apoptosis in various cancer cells. by Dec. 11 for exclusive event invite! #ASH23 #AML #MDS

Matching the RIGHT drug to the RIGHT patient is what we're all about. In an interview with our CEO, Thomas Bock highlights his own personal experience with cancer and how here at Notable we are using our platform to match oncology "diamonds in the rough" with the right patients.

RT @ycombinator: Congrats to the 2022 YC Top Companies! This year, we also launched the YC Breakthrough Companies list to highlight the f…

Wow! 4 years running - we've been listed on @ycombinator's top companies, amongst other leaders steering the future of #cancer treatment towards a more personalized one. #lifescienceleaders #predictivemedicine #personalizedmedicine #precisionmedicine

RT @KNOW_AML: Today is #AMLWorldAwarenessDay! Did you know acute myeloid #leukemia (AML) is a rare aggressive #cancer of the blood 🩸 & bone…